Jessica Witte, MD
Obesity Medicine · Olean, NYNPI 1013576545
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 314 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- GSK$1K
- Amgen$606
- Lilly USA, LLC$555
- Boehringer Ingelheim$320
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,96999%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 74 | $1,594 |
| AstraZeneca | 47 | $1,206 |
| GSK | 53 | $1,145 |
| Amgen | 30 | $606 |
| Lilly USA, LLC | 29 | $555 |
| Boehringer Ingelheim | 11 | $320 |
| Gilead | 4 | $293 |
| Bayer | 17 | $292 |
| Merck | 10 | $219 |
| Astellas Pharma US Inc | 6 | $164 |
| Exact Sciences | 8 | $156 |
| Phathom Pharmaceuticals, Inc. | 3 | $112 |
| Xeris Pharmaceuticals, Inc. | 5 | $83 |
| Pfizer | 5 | $77 |
| Johnson & Johnson | 4 | $68 |
| Lundbeck LLC | 2 | $49 |
| DJO, LLC | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 157 | $190,030 |
| FarxigaDapagliflozin Propanediol | 208 | $166,541 |
| JardianceEmpagliflozin | 100 | $126,213 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $55,053 |
| MounjaroTirzepatide | 36 | $44,504 |
| TrulicityDulaglutide | 32 | $36,743 |
| RybelsusSemaglutide | 31 | $33,801 |
| EliquisApixaban | 33 | $29,905 |
| XareltoRivaroxaban | 24 | $26,012 |
| ProliaDenosumab | 11 | $18,869 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $17,273 |
| InvokanaCanagliflozin | 14 | $11,770 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,753 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,229 |
| DapagliflozinDapagliflozin Propanediol | 13 | $7,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,594 | $223,831188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,206 | $178,294227 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $320 | $133,442112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $555 | $81,24768 claims |
| GSKTrelegy Ellipta | $1,145 | $55,05366 claims |
| Johnson & JohnsonXarelto, Invokana | $68 | $37,78238 claims |
| PfizerEliquis | $77 | $29,90533 claims |
| AmgenProlia | $606 | $18,86911 claims |
| Astellas Pharma US IncMyrbetriq | $164 | $7,20614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Olean
- Holly LoftonNew York$638K
- Terry VuongSyosset$9K
- Sarah SchmitzNew York$3K
- Duane FredericksNew York$3K
- Carol SantoroAlbany$1K
- Anelise EngelNew York$750
- Carl RuoffRoslyn Heights$348
- Thomas DoboszBuffalo$201
- Maysaa HameedRochester$187
- Nanna Oseitutu-EbanksRockville Centre$186
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.